Clinical ResearchCardiovascular RiskA Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure
Cardiovascular Risk
Under an Elsevier user license
open archive
Key Words
ACE-I
angiotensin-converting enzyme inhibitor
angiotensin receptor blocker
ARB
clinical events
Abbreviations and Acronyms
ACE-I
angiotensin-converting enzyme inhibitor
ARB
angiotensin receptor blocker
CI
confidence interval
CV
cardiovascular
DM
diabetes mellitus
HF
heart failure
IR
incidence rate
MI
myocardial infarction
OR
odds ratio
Cited by (0)
Dr. Cleland has received research funding from Servier, Amgen, and Philips; speakers' honoraria from Medtronic and St. Jude; and has participated in Trial Steering Committees with Amgen. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The first two authors contributed equally to this work.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.